In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Bard buys vascular access device supplier

This article was originally published in The Gray Sheet

Executive Summary

Bard will acquire Specialized Health Products International for $68.4 million in cash to integrate its current supplier of winged infusion sets. The sets are used to deliver therapeutic agents through vascular access ports and "help give Bard a full range of devices for port-based therapies," Bard explains. Bountiful, Utah-based SHPI reported 2007 sales of $18.9 million, reflecting organic growth of 26% over the prior year, due in part to the popularity of its safety needle products. Net income of $2.7 million last year compares to earnings of $385,000 in 2006. Bard notes that its own 2008 financial guidance "remains unchanged." SHPI expects the deal to close in the second quarter

You may also be interested in...

Goldman Sachs Gains 2 Board Seats With Burst Subscription Oral Care Investment

Series C investment of an undisclosed amount announced in early May follows $20m funding for the Los Angeles company from Volition Capital and angel investors.

Health And Wellness Trademark Review 26 May, 2020

Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.

Amivas Bests La Jolla In Race For US Approval Of Antimalarial Artesunate

La Jolla’s formulation appears blocked by Amivas’ seven-year orphan exclusivity, and the company also will miss out on chance for a tropical disease priority review voucher;  Amivas worked with the US Army to bring the severe malaria treatment through final stages of development and regulatory review.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts